12:00 AM
 | 
Feb 23, 2009
 |  BioCentury  |  Analyst Picks & Changes

Analyst picks & changes

Analyst picks & changes

Company Bank Analyst Coverage Opinion Wk chg 2/20 cls
Alexion (NASDAQ:ALXN) Needham Mark Monane New Buy -5% $37.98
Monane set a price target of $51. He estimates peak sales of $1-$1.5B for Soliris eculizumab, a mAb targeting C5 marketed to treat paroxysmal nocturnal hemoglobinuria (PNH). Monane also set his FY09 and FY10 EPS estimates at $0.74 and $1.10, respectively. He expects 2009 and 2010 revenues of $377M and $486M, respectively.
BioMarin (NASDAQ:BMRN) UBS Jeff Elliott Price target Buy -36% $11.81
Brean Murray Jonathan Aschoff ...

Read the full 689 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury

Article Purchase

$150 USD
More Info >